Physician profile
Latanya T Benjamin
NPI 1417167057
$453,304.74
in general payments reported to CMS, 2019-2025
30 companies · $96K in 2025
The $96K reported for 2025 was more than what 96% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101K · 2020: $8,621 · 2021: $15K · 2022: $45K · 2023: $57K · 2024: $132K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Consulting Fee: $72K · Travel and Lodging: $25K · Honoraria: $25K · Food and Beverage: $9,166 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150,987.50 |
| Consulting Fee | $72,483.00 |
| Travel and Lodging | $25,428.01 |
| Honoraria | $24,800.00 |
| Food and Beverage | $9,165.59 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $118,081.50 | 2019-2025 | Dupixent |
| Genzyme Corporation | $111,873.85 | 2019-2025 | |
| Incyte Corporation | $43,859.57 | 2022-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $37,327.95 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $35,596.58 | 2023-2025 | Ycanth |
| Pfizer INC. | $30,414.44 | 2019-2025 | |
| Organon LLC | $26,877.64 | 2025 | Vtama |
| Dermavant Sciences, INC. | $14,040.00 | 2024 | Vtama |
| Regeneron Pharmaceuticals, INC. | $10,015.45 | 2019 | |
| Eli Lilly and Company | $8,400.00 | 2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $6,672.13 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,998.19 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $3,057.26 | 2024-2025 | Adbry |
| Galderma Laboratories, L.P. | $2,159.67 | 2019-2025 | Nemluvio, Epsolay, Twyneo |
| Abbvie INC. | $278.08 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $137.19 | 2021 | |
| Almirall LLC | $95.12 | 2023-2024 | Seysara |
| Lilly USA, LLC | $76.65 | 2023-2025 | Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $67.56 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.34 | 2019-2024 | Cabtreo, Arazlo, Jublia |
| Janssen Biotech, INC. | $47.78 | 2019 | |
| Nobelpharma America, LLC | $26.31 | 2024 | |
| Amgen INC. | $26.24 | 2024 | Otezla |
| Aclaris Therapeutics, INC. | $23.37 | 2019 | |
| Celgene Corporation | $21.34 | 2019 | |
| Dermira, INC. | $18.39 | 2020 | |
| Melinta Therapeutics, LLC | $17.77 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.08 | 2019 | |
| Botanix Sb INC | $15.29 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $7.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latanya Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.